CA2022824C - Apparatus for an electrode and method used for iontophoresis - Google Patents
Apparatus for an electrode and method used for iontophoresisInfo
- Publication number
- CA2022824C CA2022824C CA002022824A CA2022824A CA2022824C CA 2022824 C CA2022824 C CA 2022824C CA 002022824 A CA002022824 A CA 002022824A CA 2022824 A CA2022824 A CA 2022824A CA 2022824 C CA2022824 C CA 2022824C
- Authority
- CA
- Canada
- Prior art keywords
- receivers
- transmitters
- electrode array
- source
- sides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title abstract description 15
- 150000002500 ions Chemical class 0.000 claims abstract description 43
- 229940079593 drug Drugs 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 31
- 230000005684 electric field Effects 0.000 claims abstract description 28
- 239000003792 electrolyte Substances 0.000 claims abstract description 13
- 239000011159 matrix material Substances 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 16
- 230000005540 biological transmission Effects 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 239000004020 conductor Substances 0.000 abstract description 35
- 210000003491 skin Anatomy 0.000 description 34
- 239000012212 insulator Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 11
- 210000000434 stratum corneum Anatomy 0.000 description 11
- 210000002615 epidermis Anatomy 0.000 description 7
- 238000010276 construction Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000012811 non-conductive material Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/044—Shape of the electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A61N1/303—Constructional details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
Abstract
An iontophoretic electrode has a plurality of ion transmitters for establishing electric field lines in an area and a plurality of receivers for accepting ions flowing along the field lines. A plurality of shields are located to resist ion flow between adjacent transmitters and receivers. The transmitters, shields and receivers are in at least a sequence of transmitter, shield, receiver, shield.
The electric field lines emanate substantially in one direction and return in substantially the opposite direction. The transmitters and receivers have matrix structures with space to contain ionic medication and electrolyte, respectively. A support for holding a plurality of sequences has current carrying contacts exposed to connect the transmitters and receivers in circuit with a source of electrical power. The preferred method includes establishing an electric field with lines of energy between a plurality of first and second conductors of ions and then passing ions along the energy lines between the conductors. Thereafter the method includes restricting the flow of ions to paths between adjacent first and second conductors and then positioning the first conductors relative to the second conductors so that the energy lines emanate from the first substantially in one direction return to adjacent second conductors in the opposite direction.
The electric field lines emanate substantially in one direction and return in substantially the opposite direction. The transmitters and receivers have matrix structures with space to contain ionic medication and electrolyte, respectively. A support for holding a plurality of sequences has current carrying contacts exposed to connect the transmitters and receivers in circuit with a source of electrical power. The preferred method includes establishing an electric field with lines of energy between a plurality of first and second conductors of ions and then passing ions along the energy lines between the conductors. Thereafter the method includes restricting the flow of ions to paths between adjacent first and second conductors and then positioning the first conductors relative to the second conductors so that the energy lines emanate from the first substantially in one direction return to adjacent second conductors in the opposite direction.
Description
t ~02~g24 APPARATUS FOR AN ELECTRODE AND
METHOD USED FOR IONTOP~ORESIS
Backqround of the Invention 1. Field of the Invention. This invention relates to an apparatus for an electrode and method used for iontophoresis, and more specifically, to an electrode and method for use of the electrode for iontophoretic transport of an ionic substance transdermally.
METHOD USED FOR IONTOP~ORESIS
Backqround of the Invention 1. Field of the Invention. This invention relates to an apparatus for an electrode and method used for iontophoresis, and more specifically, to an electrode and method for use of the electrode for iontophoretic transport of an ionic substance transdermally.
2. Backqround. Electrodes have been proposed for use in the transdermal delivery of ionic substances. Electromotive force used with an electrode offers the advantage of controlling the rate of delivery. Skin irritation pro~lems occur such as burns at the surface of the skin due to acids or bases formed by electrolysis of the water based medication or electrolyte. Efforts to minimize irritation have been directed to regulating the level of current, improving the electrical connection of the electrode with the skin and reducing the hydrolysis of the water used in the ionic medication and the electrolyte.
Electrode structures for transdermal drug delivery have an active electrode which delivers the ionic medication and an indifferent electrode with an electrolyte. The active and indifferent electrodes are connected to the skin forming a circuit. The )I 1~
202~824 current passes from a power source through one of the electrodes to the skin, through the the skin into the subdermal tissue, back out through the skin at a separate location and then through the other electrode. Regulation of the rate of drug delivery has been controlled by the amount of current flow and that has been limited by the electrical resistance or impedance of skin. Skin irritation is directly related to the aggressiveness of the ionic substances at the interface between the electrode and the skin and the electrical power needed to deliver the medication. The desired delivery rate often cannot be tolerated. Various power sources and electrode arrangements and constructions have been suggested to avoid burns and irritation where the iontophoresis takes place.
The efforts to use voltage levels below that required for hydrolysis as in United States Patent 4,752,285 or the use of alternating current to eliminate galvanic action are not entirely effective. The ability to deliver the preferred level of medication without skin irritation is a function of many factor,s which influence the efficiency with which any medication can be iontopheretically delivered at a preferred rate. In the past the configuration of the electrode has not been considered a factor although various electrode configurations have been proposed.
In U.S. Patent 617,543/a hollow roller electrode of any suitable cross section with wooden insulating strips between metallic conducting strips that are 2Q~8~
alternately connected to opposite sides of a source of electricity. No specific recognition of iontophoresis or disclosure of contact by more than one set of metallic strips with the skin to complete at one time more than one circuit through the skin are disclosed. Exit valves dispense medication, surround the surface of the hollow electrode which contains the medication and open when in contact with the skin.
Batteries are frequently used as a power source because of their portability and since low voltage direct current is effective. In U.S. Patents 222,2~6 and 770,014 electrode battery combinations are explained. Battery current drives medication or a conducting salt into the body. Zinc and copper electrodes form the battery and in the '276 patent the electrodes are concentric to one another; in the '014 patent the electrodes are of similar construction with surfaces which project through separating insulation. The projections may carry absorbent liquid containing pads placed between the projections and the body.
Supports for the electrodes and the power source have also included reservoirs for the ionic medication. The particular configuration of the support is a function of how much of the iontophoretic apparatus is carried in one package.
~nited States Patents 4,164,226' and -4,211,222 disclose a plurality of alternate electrode elements which are claimed to avoid iontophoretic burn by permitting current to be applied over a period of -~ i 2022~24 time. The '226 patent has small positive and negative electrodes which are spacially intermingled. The size of the positive electrodes may be the same as the negative or may be larger. A
thick porous and preferably moist material is used between the negative electrode and the skin to eliminate iontophoretic burn by preventing the migration of particles from the metallic electrode as the current passes into the skin.
Electrode structures wherein the active and the indifferent electrodes are carried on an insulator separate from each other but in position to contact the skin have taken many forms. United States Patent No. 4,32-5,367, has an electrode support structure on which is mounted a pair o electrodes in proximity to one another and a source of electrical power for the electrodes. United States Patent 4,406,568 shows an iontophoresis device with an ac~_ive electrode from which the ionic substance is driven into the body and an indifferent or ground electrode used to complete the electrical circuit through the body. The ionic substance can be positively or negatively charged but the active electrode must also be positively or negatively charged, respectively. The electrodes in United States 4,406,658'patent are adhesive so as to adhere to the skin. The electrodes are held on a support and spaced apart by a projection between them. A battery is also carried in the support and a switch for reversing the polarity of the power supply to the electrodes.
-4- =
202282~
United States Patent 4,622,031 has multilayer electrode with a peripheral contact lip as one electrode element surrounding the other electrode element. Current from a battery in that multilayer package drives the ions from the reservoir into the skin; a LED indicates current flow through the lip and into the skin by means of electrical connection to the skin with a conductive adhesive. United States Patent 4,640,689 discloses a pair of side by side active and indifferent electrodes. At least two electrode elements are within a cover partially enclosing a reservoir which is in one of the elements. A semi-permeable member in one element forms a drug gradient when power is applied from the source through a conductive adhesive to the skin.
Many materials have been suggested and used as conductive electrodes including metallic and porous natural and polymer structures depending upon what drug is desired to be delivered. United States Patent 4,708,716 discloses a plurality of cells or reservoir units with flexible separations therebetween to provide flexibility of the electrode to conform to the contours of the body. Each cell or unit is surrounded by a nonconductive gel. United States Patent 4,713,050 has a layered electrode construction with a reservoir having a cover, lip and adhesive. United States Patent 4,731,926 discloses a method of manufacture of a multi-reservoir device which is layered and rimed in configuration. The method of making the reservoirs includes occluding foam to provide insulators between the reservoirs/elements.
r~
.
United States Patent 4,734,090 discloses techniques recognizing the principle that the sweat ducts have less resistance to the flow of current and therefore ions so as to direct the current to the stratum corneum or to circumvent the stratum corneum or by using a system which plugs the entrances to the ducts. United States Patent 4,653,501 shows a electrode construction wherein the metal conductor can be reused and the electrode pad can be replaced such that the more expensive part of the electrode is retained and the body contact part of the electrode is disposable. United States Patent 4,416,274 shows an electrode for iontophoresis which has structure to inhibit the migration of ions laterally or in a direction parallel to the surface of the skin in order to decrease the likelihood of burns.
West German Patent DE 3,020,789 discloses a electrode which may be used to deliver medication applied to the body and underneath the electrode such that direct current through the electrode will drive the medication into the body. An adjustable electrode with a slidable support coupling holds adjustably positioned arms for placement of the electrodes in spaced apart relation. Thus current can be applied to different parts of the body and the spacing between the electrodes can be adjusted.
International patent application W088/00846 discloses an electrode which can be carried on a wrist belt.
Missing from these patents is the fundamental concept of having multiple active and indifferent elements separated by an insulator wherein the 20228~
spacing of the elements provides electric field lines located for transdermally delivering drug to a required depth. The unappreciated advantages of such multiple elements are improved power efficiency and the discovery that the amount of separation of the elements relates to the penetration depth of the iontophoretic delivery of medication. Improved power efficiency and the relationship of electrode spacing to depth of drug delivery result from placement of the active and indifferent elements against an insulator which sets the spacing and accordingly the depth of iontophoretic transdermal penetration.
SUMMARY OF THE INVENTION
An iontophoretic electrode array for use in transdermal transport of ionic solutions through mammalian skin has a plurality of ion transmitters for establishing electric field lines in an area and for transmission of ions along the lines. Each transmitter has a pair of longer sides and a pair of shorter sides. A plurality of receivers are positioned for accepting ions flowing along the electric field lines. Each receiver has a pair of longer sides and a pair of shorter sides. A
plurality of shields of a substance to resist the flow of ions thereacross are located between adjacent transmitters and receivers along the longer sides thereof. The preferred array has the shields interposed between adjacent transmitters and receivers so that the transmitters, shields and receivers are arranged in at least a sequence of transmitter, shield, receiver, shield.
The aspect ratio of the longer to the shorter sides of the respective transmitters and receivers is in the preferred embodiments greater than one and one half. The aspect ratio of the longer to the shorter sides of the respective transmitters and receivers is most preferably in the range of four to twenty. The electric field lines emanate substantially in one direction transversely across the longer sides of the transmitters and the receivers and the electric field lines return through the area to adjacent receivers in directions substantially opposite the one direction. The transmitters may have a matrix structure with space therein to contain ionic medication and the matrix structure is preferably a porous substance. Similarly, the receivers can have a matrix structure with space therein to contain electrolyte and also be a porous substance.
A support for holding a plurality of sequences of transmitters and receivers separated by interposed shields may be included on the array. The support has current carrying contacts positioned thereon and exposed to connect the transmitters and receivers in circuit with a source of electrical power. In addition, the source of electrical power is preferably carried in ~he support.
In one form of the array the transmitters and receivers are rectangular plate like in shape with a pair of opposed parallel major surfaces bound by sides set perpendicular thereto and a first set of current carrying contacts are connected in circuit with the source of electrical power and are exposed to connect with one of the sides of each of the transmitters. Similarly, the support has a second set of current carrying contacts positioned thereon and exposed to connect one of the sides of each of the receivers in circuit with the source of electrical power. The first and second sets of the contacts are mounted on the support in spaced apart relation relative to each other and are located on a face thereof. The first set of contacts connected to the transmitters are arranged in circuit for passing electrons between the source of electrical power to the transmitters, and the second set of contacts connected to the receivers are arranged in circuit for passing electrons between the receives and the power sources so that there is current flow from the source of electrical power to the transmitters and there is current flow from the receivers to the source of electrical power when ions flow between the sides of the transmitters opposite the first set of contacts and the adjacent sides of the receivers opposite the second set of contacts through the skin. The support may include recesses so that each shield may extend beyond the face thereon into one recess.
The array may be used to deliver ionic medication by iontophoresis in a preferred method including establishing an electric field having lines of energy between a plurality of first conductors of ions and a plurality of second conductors of ions. The method has the next step of passing ions along the energy lines of the electric field from the first to the second conductors and through a resistive medium.
Thereafter the method includes restricting the flow of ions to paths between adjacent first and second conductors defined by the energy lines of the 20~2~24 electric field. The method has the step of positioning the irst conductors relative to the second conductors so that the energy lines emanate therefrom substantially in one direction return to the adjacent second conductors in another direction opposite the one direction.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is an exploded perspective view of the preferred embodiment of an ionotophoretic electrode array.
Figure 2 is an exploded perspective view of an alternate iontophoretic electrode array.
Figure 3 is an exploded schematic of an alternate iontophoretic electrode illustrated in perspective.
Figure 4 is a graph of current density relative to skin damage for experiments with a pair of spaced electrodes and with arrays of the type disclosed in Figures 1,2 or 3.
Figure 5 is a schematic side elevational view of the pair of spaced electrodes used to obtain some of the data in the graph of Figure 4.
DETAIL DESCRIPTION
While this invention is satisfied by embodiments in many different forms, there is shown in the drawings and will herein be described in detail a 202~824 preferred embodiment and alternate embodiments of the invention, with the understanding that the present disclosure is to be considered as exemplary of the principles of the inve~tion and is not intended to limit the invention to the embodiments illustrated.
The scope of the invention will ~e measured by the appended claims and their equivalents.
An iontophoretic electrode array 10 for placement against the skin during transdermal transport of ionic solutions through mammalian skin is shown in perspective in Figure 1. The array 10 has a plurality of ion transmitters 11 for establishing electric field lines 12 in an area A for placement against the skin and for transmission of ions along the field lines 12. Each transmitter 11 is configured to have a pair of longer sides 13 and a pair of shorter sides 14. The array 10 also includes a plurality of receivers 15 in position for accepting ions flowing along the electric field lines 12 in the area A of the skin. The shape of each recei~er 15 has a pair of longer sides 16 and a pair of shorter sides 17.
A plurality of shields 18, made of a substance to resist the flow of ions thereacross, are in the array 10. The shields 18 are interposed and located between adjacent transmitters 11 and receivers 15 in between the longer sides 13 and 16 thereof so that the transmitters 11, shields 18 and receivers 15 are arranged in at least a sequence of transmitter 11, shield 18, receiver 15, shield 18. The electric field lines 12 are generally transverse to the longer sides 13 and 16 as they pass through the area A of the skin.
The aspect ratio of the longer sides 13 and 16 to the shorter sides 14 and 17 of the respective transmitters 11 and receivers 15 is greater than one and one half to one. The preferred range for the aspect ratio between four and twenty for the longer sides 13 and 16 to the respective shorter sides 14 and 17. The transmitters 11 are ma~e of a material which contains ionic medication. The material is a porous substance with space therein to contain ionic medication. The material in one form of the invention is a hydrogel formulated ~o include the ionic medication.
The receivers 15 include a material ~hich contains an electrolyte. The material is a porous substance with space therein to contain the electrolyte. The material in one form of the invention is a hydrogel so formulated to include the electrolyte. The transmitters 11 could alternatively be a matrix structure with space therein to contain ionic medication and likewise the receivers 15 could have a matrix structure with space therein to contain electrolyte. The matrix structure is a porous su~stance such as Porex The electrode array has a support 19 for holding a plurality of sequences of transmitters 11 and receivers 15 separated by interposed shields 18. The support 19 has current carrying contacts 20 *Trademark -12-~, ~
, .~
202282!1 positioned thereon and exposed to connect thetransmitters 11 and receivers 15 in circuit with a source of electrical power 21. The source of electrical power 21 is carried in the support 19.
The transmitters 11 and receivers 15 are rectangular plate like in shape with the pair of longer sides 13 and 16 being opposed parallel major surfaces 22 and 23 bound by the shorter sides 14 and 17 perpendicular thereto. In one form of the array 10 the support 19 has a first set of current carrying contacts 24 connected in circuit with the source of electrical power 21 and positioned thereon and exposed to connect to the top of each of the transmitters 11 and wherein the support 19 has a second set of current carrying contacts 25 positioned thereon and exposed to connect the top of each of the receivers 15 in circuit with the source of electrical power 21.
The first and second sets of the contacts 24 and are mounted on the support 19 in spaced apart relation relative to each other and are located on a face 26 thereof, the first set of contacts 24 connected to the transmitters 11 are arranged in circuit for passing current from the source of electrical power 21 to the transmitters 11 and the second set of contacts 25 connected to the receivers 15 are arranged in circuit for receiving ions from the receivers 15 so that there is current flow from the source of electrical power 21 to the transmitters 11 and there is current flow from the receivers 15 to the source of electrical power 21 when ions flow between the sides of thé transmitters 11 opposite the first set of contacts 24 and the adjacent sides of the receivers 15 opposite the second set of contacts 25.
-~ ~02282~
The support 19 includes recesses 27 and each shield 18 when assembled extends beyond the face 26 thereon for the first and second contact sets 24 and 2S into one recess 27 in the support 19 so that each recess 27 locates the transmitters 11 and the first set of contacts 24 in circuit and aligns the receivers 15 and the second set of contacts 25 in clrcult .
In Figure 2 an alternate embodiment of an array 10' has a plurality of active members 28, each active member 28 generally rectangular in shape and having a pair of longer sides 29 opposite each other. Each active member 28 is made of a material for containing an ionic medication solution. A plurality of indifferent members 30 iS in the array 10' and each indifferent member 30 is of generally rectangular shape having a pair of longer sides 31 opposite each other. Each indifferent member 30 is made of a material for containing an ele~trolyte solution. A
plurality of insulators 32 is included in the array 10' so each insulator 32 has a pair of sides 33 opposite each other and each insulator 32 iS when assembled placed in side 33 against side 33 contact with and between the active and indifferent members 28 and 30 forming the array 10' having at least the sequence of active member 28, insulator 32, indifferent member 30, insulator 32.
The placement of the insulators 32 iS such that the longer sides 29 and 31 of the generally rectangular active and indifferent members 28 and 30 are against the insulators 32 in the sequence.
202282~
Because of the generally rectangular shape the aspect ratio of the longer to the shorter sides 34 and 35 of the respective active and indifferent members 28 and is greater than one and one half to one. The aspect ratio of the longer sides 29 and 31 to the shorter sides 34 and 35 of the respective active and indifferent members 28 and 30 is preferably in the range of four to twenty.
The array 10' includes a support 36 for holding a plurality of active members 28 and indifferent members 30 separated by interposed insulators 32.
The support 36 carries contacts 37 positioned thereon and exposed to connect the active and indifferent members 28 and 30 in circuit with a source of electric power 38. The source of electric power 38 is carried by the support 36. The longer sides 29 and 31 of the active and indifferent members 28 and 30 are major surfaces 39 and 40 respectively, with each of the members 28 or 30 having a pair of opposed marginal planes 41 for the active member 28 and 42 for the indifferent member, wherein the planes 41 and 42 are located normal to the major surfaces 39 and 40, respectively.
The support 36 has contacts 37 shown in the cut away portion of the support 36 of Figure 2, includes a first set of current carrying contacts 24' connected in circuit with the source of electrical power 38 and positioned on the support 36 and exposed to connect with one of the marginal planes 41 of each of the active members 28. The support 36 has a second set of current carrying con~acts 25' in circuit with the source of electrical power 38 and positioned thereon and exposed to connect with one of the marginal planes 42 of each of the indifferent members 30. The first and second sets of the contacts 24 ' and 25' are mounted on the support 36 in spaced apart relation relative to each other and are located on a face 43 thereof; the first set of contacts 24' connected to the active members 28 are arranged in circuit for passing current from the source of electrical power 38 to the active members 28 and the second set of contacts 25' connected to the indifferent members 25' arranged in circuit for passing current to the source of electrical power 38 so that there is current flow from the source of electrical power to the active members 28 and there is current flow from the indifferent members 30 to the source of electrical power 38 when there are ions flowing along electrical field lines 12 ' between active members 28 opposite the first set of contacts 24' and indifferent members 30 opposite the second set of contacts 25'.
In this form of the array 10~ the insulator 32 between each of the active and indifferent members 28 and 30 respectively, extends beyond the face 43 thereof for locating the first and second sets of contacts 24' and 2S' and the support 36 has a plurality of grooves 44 positioned to locate the active members 28 and the first set of contacts 24 ' in circuit and to align the indifferent members 30 and the second set of contacts 25' in circuit when the active and indifferent members 28 and 30, insulators 32 and the support 36 are assembled with the major surfaces 39 and 40 thereof against the insulators 32 therebetween.
The active members 28 have a matrix structure with space therein to contain ionic medication and the indifferent members 32 have a matrix structure with space therein to contain electrolyte. The matrix lS a porous polymer of polyethylene.
An alternate iontophoresis electrode 45 shown schematically in Figure 3, has a plurality of first conductors 46 electrically connected in parallel to a first output 47 of a source of electrical power 48.
Each of the first conductors 46 has an elongate configuration bound on opposite sides and made of a material to readily pass ions thereacross. A
plurality of second conductors 49 in the electrode 45 is electrically connected in parallel to second output 50 of the source of electrical power 48. Each of the second conductors 49 has an elongate configuration bound on opposite sides and made of a material to readily pass ions thereacross. A
plurality of insulators 51 of electrically non conductive material are in the electrode 45. Each of the insulators 51 has an elongate configuration bound on opposite sides and is made of a material which resists the passage of ions thereacross.
The placement of the insulator 51 material which resists the flow of ions is such that longer sides 52 and 53 of the elongate first and second conductors 46 and 49 are against the insulator 51 material which 2~22824 resists the flow of ions. Because of the generally elongate shape the aspect ratio of the longer sides 52 and 53 to the shorter sides 54 and 55 of the respective first and second electrical conductors 46 and 49 is greater than one and one half to one. The aspect ratio of the longer to the shorter sides of the respective first and second conductors 46 and 49 is preferably in the range of four to twenty. The insulator 51 material which resists the flow of ions is interposed between first and second conductors 46 and 49 for forming a sandwich construction.
A support 56 is attached to the electrode 45 with a plurality of first contacts 57 are positioned in spaced apart relation thereon on a face 58 thereof.
The first contacts 57 are electrically connected in a first parallel circuit with the source of electrical power 48 such as a battery and one side 59 of each of the first conductors 46. The support 56 has a plurality of second contacts 60 positioned thereon on the face 58 thereof and in spaced apart relation.
The second contacts 60 are electrically connected in a second parallel circuit with the source of electrical power 59 and one side of each of the second conductors 49.
Although schematically shown within a dashed line, the support 56 carries above the face 58 the source of electrical power 48. The support 56 includes a reservoir 61 in fluid connection with the first conductors 46 and adapted to contain ionic material for transdermal transport by the first conductors 46. The reservoir 61 is detachably contained on the support 56 so that the reservoir 61 can be removed and replaced.
A method of using an iontophoresis electrode 45 for transdermal transport of an ionic substance is also a part of this invention. The method includes the steps of establishing electric field lines 12 of energy between the plurality of first conductors 46 of ions and the plurality of second conductors 49 of ions. Then the method includes the step of passing ions along the energy lines 12 of the electric field from between the plurality of first to the second conductors 46 and 49 and through a semiconductive medium. Thereafter the step includes restricting the flow of ions to paths between adjacent first and second conductors 46 and 49 defined by the energy lines 12 of the electric field. The next step is positioning the first conductors 46 relative to the second conductors 49 so that the energy lines 12 emanate therefrom substantially in one direction return to the ad~acent second conductors 49 in another direction opposite the one direction shown as perpendicular to the skin by arrow B, in Figures 1 and 3.
The thickness of the shields 18 or insulators 32 or 51 has a an effect upon how deeply the ionic solution is transported into the skin. For a range of thickness between very thick and very thin shields 18 or insulators 32 or 51, the electric field lines 12 are still relatively short, and hence require relatively low energy to transport the ionic ;.
solution. The electric field lines 12 are sufficiently long, however, so that the ionic solution is still transported by the electric field lines 12 to the epidermis at C and dermis at D for transfer to the vasculature at E. To some extent, the preferred range extends from 0.01 to 1.0 inches or .025 to 2.s centimeters. The most beneficial range is 0.10 to 0.62 centimeters.
The stratum corneum at F is essentially unhydrated protein. Since there are few ions in that material the impedence is high. The granulated epidermis C is the sight of transformation from the well hydrated basal epidermis C to the unhydrated stratum corneum F. Here the impedence falls off as the tissue increases in hydration, also because of salt content. From the basal epidermis C inward, tissues are well hydrated, and salt solutions isotonic whereby the impedence nears its minimum. Of course, the impedence will vary from person to person and place to place on any given person, however, it is known that the impedence is high at the stratum corneum F gradually decreasing to the granulated epidermis where it drops significantly and remains low into and through the basal epidermis C and the dermis D. For very thin shields 18 or insulators 32 or 51 in a repeated array 10 or 10' or in an electrode 45 such as disclosed and described as the embodiments in this specification, the electric field lines 12 pass through the stratum corneum F and maybe the upper layers of the granulated epidermis C.
, , 20228~
These paths are preferred in spite of the high resisitivity or impedence of the stratum corneum F
because the path lengths of the electric field lines 12 are short. Since ionic solution flows during transportation along the electric field lines 12, it can be appreciated that the ionic solution is transported well into the stratum corneum F then flows backup to the receiver. Thus, for very thin insulators, little of the medication reaches the blood stream. Moreover, this approach has the greatest likelihood to actually short out due to the close spacing of either the transmitters and receivers 11 and 15, the active and indifferent members 28 and 30 or the first and second conductors 46 and 49.
If the shields 18 or insulators 32 or 51 are very thick, the electric field lines 12 lengthen as they take the path of least impedence through the stratum corneum F and the hydrated tissue C below the stratum corneum F so they may return through the stratum corneum F to the next adjacent transmitter 11 or receiver 15, member 28 or 30, or conductor 46 or 49, requiring greater levels of energy. This path is most effective for transportation of ionic solution to the dermis D, however, it requires the greatest amount of energy which increases the amount of skin damage or irritation. An optimum thickness of insulator 32 or 51 or shield 18 exists wherein the field lines are deep enough to cause ions to reach the bloodstream, and the length of each field line is short enough to minimize skin irritation.
2~22824 Figure 4 is a plot on a graph of the petechial skin damage of an experiment with iontophoretically transported lidocaine. Along the vertical axis of that graph is shown the damage assessment score which is the number of petechial (small, punctate, red spots in the skin) observed under the electrode.
This axis is linearly divided, the horizontal axis shows current density necessary in order to transport ionic solution. The current density is in microamps per sguare centimeter and the scale is a log scale.
The significant data are represented by two areas of the plot. The first area of the graph is plotted above the current density range of 25. to 75 microamperes per square centimeter for a typical iontophoretic electrode of the type in Figure S
wherein the active and indifferent members are spaced apart and are of no particular shape as can be seen, damage to the skin begins to occur at current densities of about 25 The second plot of data in the range of 500 to 1000 microamperes per square centimeter represent the experiments with the claimed invention. The difference in these data are apparent in that the amount of current density that can be used without damage to the skin is at least ten times greater than with the typical electrode in Figure 5. Another way of looking at the data is that current between 100 and 500 microamperes per square centimeter can be used to transport drug without measurable damage using this invention. Note that several data points are not typical of that which is expected; those data points show the difficulty of transportation caused by variations of impedence of the skin. These particular data were obtained during experiments with pigs where the damage was assessed after each test upon a different area of the animal's skin.
The specific material described and the particular configurations of the preferred and alternate embodiments may be changed without departing from the scope of the invention covered by the claims which follow.
Electrode structures for transdermal drug delivery have an active electrode which delivers the ionic medication and an indifferent electrode with an electrolyte. The active and indifferent electrodes are connected to the skin forming a circuit. The )I 1~
202~824 current passes from a power source through one of the electrodes to the skin, through the the skin into the subdermal tissue, back out through the skin at a separate location and then through the other electrode. Regulation of the rate of drug delivery has been controlled by the amount of current flow and that has been limited by the electrical resistance or impedance of skin. Skin irritation is directly related to the aggressiveness of the ionic substances at the interface between the electrode and the skin and the electrical power needed to deliver the medication. The desired delivery rate often cannot be tolerated. Various power sources and electrode arrangements and constructions have been suggested to avoid burns and irritation where the iontophoresis takes place.
The efforts to use voltage levels below that required for hydrolysis as in United States Patent 4,752,285 or the use of alternating current to eliminate galvanic action are not entirely effective. The ability to deliver the preferred level of medication without skin irritation is a function of many factor,s which influence the efficiency with which any medication can be iontopheretically delivered at a preferred rate. In the past the configuration of the electrode has not been considered a factor although various electrode configurations have been proposed.
In U.S. Patent 617,543/a hollow roller electrode of any suitable cross section with wooden insulating strips between metallic conducting strips that are 2Q~8~
alternately connected to opposite sides of a source of electricity. No specific recognition of iontophoresis or disclosure of contact by more than one set of metallic strips with the skin to complete at one time more than one circuit through the skin are disclosed. Exit valves dispense medication, surround the surface of the hollow electrode which contains the medication and open when in contact with the skin.
Batteries are frequently used as a power source because of their portability and since low voltage direct current is effective. In U.S. Patents 222,2~6 and 770,014 electrode battery combinations are explained. Battery current drives medication or a conducting salt into the body. Zinc and copper electrodes form the battery and in the '276 patent the electrodes are concentric to one another; in the '014 patent the electrodes are of similar construction with surfaces which project through separating insulation. The projections may carry absorbent liquid containing pads placed between the projections and the body.
Supports for the electrodes and the power source have also included reservoirs for the ionic medication. The particular configuration of the support is a function of how much of the iontophoretic apparatus is carried in one package.
~nited States Patents 4,164,226' and -4,211,222 disclose a plurality of alternate electrode elements which are claimed to avoid iontophoretic burn by permitting current to be applied over a period of -~ i 2022~24 time. The '226 patent has small positive and negative electrodes which are spacially intermingled. The size of the positive electrodes may be the same as the negative or may be larger. A
thick porous and preferably moist material is used between the negative electrode and the skin to eliminate iontophoretic burn by preventing the migration of particles from the metallic electrode as the current passes into the skin.
Electrode structures wherein the active and the indifferent electrodes are carried on an insulator separate from each other but in position to contact the skin have taken many forms. United States Patent No. 4,32-5,367, has an electrode support structure on which is mounted a pair o electrodes in proximity to one another and a source of electrical power for the electrodes. United States Patent 4,406,568 shows an iontophoresis device with an ac~_ive electrode from which the ionic substance is driven into the body and an indifferent or ground electrode used to complete the electrical circuit through the body. The ionic substance can be positively or negatively charged but the active electrode must also be positively or negatively charged, respectively. The electrodes in United States 4,406,658'patent are adhesive so as to adhere to the skin. The electrodes are held on a support and spaced apart by a projection between them. A battery is also carried in the support and a switch for reversing the polarity of the power supply to the electrodes.
-4- =
202282~
United States Patent 4,622,031 has multilayer electrode with a peripheral contact lip as one electrode element surrounding the other electrode element. Current from a battery in that multilayer package drives the ions from the reservoir into the skin; a LED indicates current flow through the lip and into the skin by means of electrical connection to the skin with a conductive adhesive. United States Patent 4,640,689 discloses a pair of side by side active and indifferent electrodes. At least two electrode elements are within a cover partially enclosing a reservoir which is in one of the elements. A semi-permeable member in one element forms a drug gradient when power is applied from the source through a conductive adhesive to the skin.
Many materials have been suggested and used as conductive electrodes including metallic and porous natural and polymer structures depending upon what drug is desired to be delivered. United States Patent 4,708,716 discloses a plurality of cells or reservoir units with flexible separations therebetween to provide flexibility of the electrode to conform to the contours of the body. Each cell or unit is surrounded by a nonconductive gel. United States Patent 4,713,050 has a layered electrode construction with a reservoir having a cover, lip and adhesive. United States Patent 4,731,926 discloses a method of manufacture of a multi-reservoir device which is layered and rimed in configuration. The method of making the reservoirs includes occluding foam to provide insulators between the reservoirs/elements.
r~
.
United States Patent 4,734,090 discloses techniques recognizing the principle that the sweat ducts have less resistance to the flow of current and therefore ions so as to direct the current to the stratum corneum or to circumvent the stratum corneum or by using a system which plugs the entrances to the ducts. United States Patent 4,653,501 shows a electrode construction wherein the metal conductor can be reused and the electrode pad can be replaced such that the more expensive part of the electrode is retained and the body contact part of the electrode is disposable. United States Patent 4,416,274 shows an electrode for iontophoresis which has structure to inhibit the migration of ions laterally or in a direction parallel to the surface of the skin in order to decrease the likelihood of burns.
West German Patent DE 3,020,789 discloses a electrode which may be used to deliver medication applied to the body and underneath the electrode such that direct current through the electrode will drive the medication into the body. An adjustable electrode with a slidable support coupling holds adjustably positioned arms for placement of the electrodes in spaced apart relation. Thus current can be applied to different parts of the body and the spacing between the electrodes can be adjusted.
International patent application W088/00846 discloses an electrode which can be carried on a wrist belt.
Missing from these patents is the fundamental concept of having multiple active and indifferent elements separated by an insulator wherein the 20228~
spacing of the elements provides electric field lines located for transdermally delivering drug to a required depth. The unappreciated advantages of such multiple elements are improved power efficiency and the discovery that the amount of separation of the elements relates to the penetration depth of the iontophoretic delivery of medication. Improved power efficiency and the relationship of electrode spacing to depth of drug delivery result from placement of the active and indifferent elements against an insulator which sets the spacing and accordingly the depth of iontophoretic transdermal penetration.
SUMMARY OF THE INVENTION
An iontophoretic electrode array for use in transdermal transport of ionic solutions through mammalian skin has a plurality of ion transmitters for establishing electric field lines in an area and for transmission of ions along the lines. Each transmitter has a pair of longer sides and a pair of shorter sides. A plurality of receivers are positioned for accepting ions flowing along the electric field lines. Each receiver has a pair of longer sides and a pair of shorter sides. A
plurality of shields of a substance to resist the flow of ions thereacross are located between adjacent transmitters and receivers along the longer sides thereof. The preferred array has the shields interposed between adjacent transmitters and receivers so that the transmitters, shields and receivers are arranged in at least a sequence of transmitter, shield, receiver, shield.
The aspect ratio of the longer to the shorter sides of the respective transmitters and receivers is in the preferred embodiments greater than one and one half. The aspect ratio of the longer to the shorter sides of the respective transmitters and receivers is most preferably in the range of four to twenty. The electric field lines emanate substantially in one direction transversely across the longer sides of the transmitters and the receivers and the electric field lines return through the area to adjacent receivers in directions substantially opposite the one direction. The transmitters may have a matrix structure with space therein to contain ionic medication and the matrix structure is preferably a porous substance. Similarly, the receivers can have a matrix structure with space therein to contain electrolyte and also be a porous substance.
A support for holding a plurality of sequences of transmitters and receivers separated by interposed shields may be included on the array. The support has current carrying contacts positioned thereon and exposed to connect the transmitters and receivers in circuit with a source of electrical power. In addition, the source of electrical power is preferably carried in ~he support.
In one form of the array the transmitters and receivers are rectangular plate like in shape with a pair of opposed parallel major surfaces bound by sides set perpendicular thereto and a first set of current carrying contacts are connected in circuit with the source of electrical power and are exposed to connect with one of the sides of each of the transmitters. Similarly, the support has a second set of current carrying contacts positioned thereon and exposed to connect one of the sides of each of the receivers in circuit with the source of electrical power. The first and second sets of the contacts are mounted on the support in spaced apart relation relative to each other and are located on a face thereof. The first set of contacts connected to the transmitters are arranged in circuit for passing electrons between the source of electrical power to the transmitters, and the second set of contacts connected to the receivers are arranged in circuit for passing electrons between the receives and the power sources so that there is current flow from the source of electrical power to the transmitters and there is current flow from the receivers to the source of electrical power when ions flow between the sides of the transmitters opposite the first set of contacts and the adjacent sides of the receivers opposite the second set of contacts through the skin. The support may include recesses so that each shield may extend beyond the face thereon into one recess.
The array may be used to deliver ionic medication by iontophoresis in a preferred method including establishing an electric field having lines of energy between a plurality of first conductors of ions and a plurality of second conductors of ions. The method has the next step of passing ions along the energy lines of the electric field from the first to the second conductors and through a resistive medium.
Thereafter the method includes restricting the flow of ions to paths between adjacent first and second conductors defined by the energy lines of the 20~2~24 electric field. The method has the step of positioning the irst conductors relative to the second conductors so that the energy lines emanate therefrom substantially in one direction return to the adjacent second conductors in another direction opposite the one direction.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is an exploded perspective view of the preferred embodiment of an ionotophoretic electrode array.
Figure 2 is an exploded perspective view of an alternate iontophoretic electrode array.
Figure 3 is an exploded schematic of an alternate iontophoretic electrode illustrated in perspective.
Figure 4 is a graph of current density relative to skin damage for experiments with a pair of spaced electrodes and with arrays of the type disclosed in Figures 1,2 or 3.
Figure 5 is a schematic side elevational view of the pair of spaced electrodes used to obtain some of the data in the graph of Figure 4.
DETAIL DESCRIPTION
While this invention is satisfied by embodiments in many different forms, there is shown in the drawings and will herein be described in detail a 202~824 preferred embodiment and alternate embodiments of the invention, with the understanding that the present disclosure is to be considered as exemplary of the principles of the inve~tion and is not intended to limit the invention to the embodiments illustrated.
The scope of the invention will ~e measured by the appended claims and their equivalents.
An iontophoretic electrode array 10 for placement against the skin during transdermal transport of ionic solutions through mammalian skin is shown in perspective in Figure 1. The array 10 has a plurality of ion transmitters 11 for establishing electric field lines 12 in an area A for placement against the skin and for transmission of ions along the field lines 12. Each transmitter 11 is configured to have a pair of longer sides 13 and a pair of shorter sides 14. The array 10 also includes a plurality of receivers 15 in position for accepting ions flowing along the electric field lines 12 in the area A of the skin. The shape of each recei~er 15 has a pair of longer sides 16 and a pair of shorter sides 17.
A plurality of shields 18, made of a substance to resist the flow of ions thereacross, are in the array 10. The shields 18 are interposed and located between adjacent transmitters 11 and receivers 15 in between the longer sides 13 and 16 thereof so that the transmitters 11, shields 18 and receivers 15 are arranged in at least a sequence of transmitter 11, shield 18, receiver 15, shield 18. The electric field lines 12 are generally transverse to the longer sides 13 and 16 as they pass through the area A of the skin.
The aspect ratio of the longer sides 13 and 16 to the shorter sides 14 and 17 of the respective transmitters 11 and receivers 15 is greater than one and one half to one. The preferred range for the aspect ratio between four and twenty for the longer sides 13 and 16 to the respective shorter sides 14 and 17. The transmitters 11 are ma~e of a material which contains ionic medication. The material is a porous substance with space therein to contain ionic medication. The material in one form of the invention is a hydrogel formulated ~o include the ionic medication.
The receivers 15 include a material ~hich contains an electrolyte. The material is a porous substance with space therein to contain the electrolyte. The material in one form of the invention is a hydrogel so formulated to include the electrolyte. The transmitters 11 could alternatively be a matrix structure with space therein to contain ionic medication and likewise the receivers 15 could have a matrix structure with space therein to contain electrolyte. The matrix structure is a porous su~stance such as Porex The electrode array has a support 19 for holding a plurality of sequences of transmitters 11 and receivers 15 separated by interposed shields 18. The support 19 has current carrying contacts 20 *Trademark -12-~, ~
, .~
202282!1 positioned thereon and exposed to connect thetransmitters 11 and receivers 15 in circuit with a source of electrical power 21. The source of electrical power 21 is carried in the support 19.
The transmitters 11 and receivers 15 are rectangular plate like in shape with the pair of longer sides 13 and 16 being opposed parallel major surfaces 22 and 23 bound by the shorter sides 14 and 17 perpendicular thereto. In one form of the array 10 the support 19 has a first set of current carrying contacts 24 connected in circuit with the source of electrical power 21 and positioned thereon and exposed to connect to the top of each of the transmitters 11 and wherein the support 19 has a second set of current carrying contacts 25 positioned thereon and exposed to connect the top of each of the receivers 15 in circuit with the source of electrical power 21.
The first and second sets of the contacts 24 and are mounted on the support 19 in spaced apart relation relative to each other and are located on a face 26 thereof, the first set of contacts 24 connected to the transmitters 11 are arranged in circuit for passing current from the source of electrical power 21 to the transmitters 11 and the second set of contacts 25 connected to the receivers 15 are arranged in circuit for receiving ions from the receivers 15 so that there is current flow from the source of electrical power 21 to the transmitters 11 and there is current flow from the receivers 15 to the source of electrical power 21 when ions flow between the sides of thé transmitters 11 opposite the first set of contacts 24 and the adjacent sides of the receivers 15 opposite the second set of contacts 25.
-~ ~02282~
The support 19 includes recesses 27 and each shield 18 when assembled extends beyond the face 26 thereon for the first and second contact sets 24 and 2S into one recess 27 in the support 19 so that each recess 27 locates the transmitters 11 and the first set of contacts 24 in circuit and aligns the receivers 15 and the second set of contacts 25 in clrcult .
In Figure 2 an alternate embodiment of an array 10' has a plurality of active members 28, each active member 28 generally rectangular in shape and having a pair of longer sides 29 opposite each other. Each active member 28 is made of a material for containing an ionic medication solution. A plurality of indifferent members 30 iS in the array 10' and each indifferent member 30 is of generally rectangular shape having a pair of longer sides 31 opposite each other. Each indifferent member 30 is made of a material for containing an ele~trolyte solution. A
plurality of insulators 32 is included in the array 10' so each insulator 32 has a pair of sides 33 opposite each other and each insulator 32 iS when assembled placed in side 33 against side 33 contact with and between the active and indifferent members 28 and 30 forming the array 10' having at least the sequence of active member 28, insulator 32, indifferent member 30, insulator 32.
The placement of the insulators 32 iS such that the longer sides 29 and 31 of the generally rectangular active and indifferent members 28 and 30 are against the insulators 32 in the sequence.
202282~
Because of the generally rectangular shape the aspect ratio of the longer to the shorter sides 34 and 35 of the respective active and indifferent members 28 and is greater than one and one half to one. The aspect ratio of the longer sides 29 and 31 to the shorter sides 34 and 35 of the respective active and indifferent members 28 and 30 is preferably in the range of four to twenty.
The array 10' includes a support 36 for holding a plurality of active members 28 and indifferent members 30 separated by interposed insulators 32.
The support 36 carries contacts 37 positioned thereon and exposed to connect the active and indifferent members 28 and 30 in circuit with a source of electric power 38. The source of electric power 38 is carried by the support 36. The longer sides 29 and 31 of the active and indifferent members 28 and 30 are major surfaces 39 and 40 respectively, with each of the members 28 or 30 having a pair of opposed marginal planes 41 for the active member 28 and 42 for the indifferent member, wherein the planes 41 and 42 are located normal to the major surfaces 39 and 40, respectively.
The support 36 has contacts 37 shown in the cut away portion of the support 36 of Figure 2, includes a first set of current carrying contacts 24' connected in circuit with the source of electrical power 38 and positioned on the support 36 and exposed to connect with one of the marginal planes 41 of each of the active members 28. The support 36 has a second set of current carrying con~acts 25' in circuit with the source of electrical power 38 and positioned thereon and exposed to connect with one of the marginal planes 42 of each of the indifferent members 30. The first and second sets of the contacts 24 ' and 25' are mounted on the support 36 in spaced apart relation relative to each other and are located on a face 43 thereof; the first set of contacts 24' connected to the active members 28 are arranged in circuit for passing current from the source of electrical power 38 to the active members 28 and the second set of contacts 25' connected to the indifferent members 25' arranged in circuit for passing current to the source of electrical power 38 so that there is current flow from the source of electrical power to the active members 28 and there is current flow from the indifferent members 30 to the source of electrical power 38 when there are ions flowing along electrical field lines 12 ' between active members 28 opposite the first set of contacts 24' and indifferent members 30 opposite the second set of contacts 25'.
In this form of the array 10~ the insulator 32 between each of the active and indifferent members 28 and 30 respectively, extends beyond the face 43 thereof for locating the first and second sets of contacts 24' and 2S' and the support 36 has a plurality of grooves 44 positioned to locate the active members 28 and the first set of contacts 24 ' in circuit and to align the indifferent members 30 and the second set of contacts 25' in circuit when the active and indifferent members 28 and 30, insulators 32 and the support 36 are assembled with the major surfaces 39 and 40 thereof against the insulators 32 therebetween.
The active members 28 have a matrix structure with space therein to contain ionic medication and the indifferent members 32 have a matrix structure with space therein to contain electrolyte. The matrix lS a porous polymer of polyethylene.
An alternate iontophoresis electrode 45 shown schematically in Figure 3, has a plurality of first conductors 46 electrically connected in parallel to a first output 47 of a source of electrical power 48.
Each of the first conductors 46 has an elongate configuration bound on opposite sides and made of a material to readily pass ions thereacross. A
plurality of second conductors 49 in the electrode 45 is electrically connected in parallel to second output 50 of the source of electrical power 48. Each of the second conductors 49 has an elongate configuration bound on opposite sides and made of a material to readily pass ions thereacross. A
plurality of insulators 51 of electrically non conductive material are in the electrode 45. Each of the insulators 51 has an elongate configuration bound on opposite sides and is made of a material which resists the passage of ions thereacross.
The placement of the insulator 51 material which resists the flow of ions is such that longer sides 52 and 53 of the elongate first and second conductors 46 and 49 are against the insulator 51 material which 2~22824 resists the flow of ions. Because of the generally elongate shape the aspect ratio of the longer sides 52 and 53 to the shorter sides 54 and 55 of the respective first and second electrical conductors 46 and 49 is greater than one and one half to one. The aspect ratio of the longer to the shorter sides of the respective first and second conductors 46 and 49 is preferably in the range of four to twenty. The insulator 51 material which resists the flow of ions is interposed between first and second conductors 46 and 49 for forming a sandwich construction.
A support 56 is attached to the electrode 45 with a plurality of first contacts 57 are positioned in spaced apart relation thereon on a face 58 thereof.
The first contacts 57 are electrically connected in a first parallel circuit with the source of electrical power 48 such as a battery and one side 59 of each of the first conductors 46. The support 56 has a plurality of second contacts 60 positioned thereon on the face 58 thereof and in spaced apart relation.
The second contacts 60 are electrically connected in a second parallel circuit with the source of electrical power 59 and one side of each of the second conductors 49.
Although schematically shown within a dashed line, the support 56 carries above the face 58 the source of electrical power 48. The support 56 includes a reservoir 61 in fluid connection with the first conductors 46 and adapted to contain ionic material for transdermal transport by the first conductors 46. The reservoir 61 is detachably contained on the support 56 so that the reservoir 61 can be removed and replaced.
A method of using an iontophoresis electrode 45 for transdermal transport of an ionic substance is also a part of this invention. The method includes the steps of establishing electric field lines 12 of energy between the plurality of first conductors 46 of ions and the plurality of second conductors 49 of ions. Then the method includes the step of passing ions along the energy lines 12 of the electric field from between the plurality of first to the second conductors 46 and 49 and through a semiconductive medium. Thereafter the step includes restricting the flow of ions to paths between adjacent first and second conductors 46 and 49 defined by the energy lines 12 of the electric field. The next step is positioning the first conductors 46 relative to the second conductors 49 so that the energy lines 12 emanate therefrom substantially in one direction return to the ad~acent second conductors 49 in another direction opposite the one direction shown as perpendicular to the skin by arrow B, in Figures 1 and 3.
The thickness of the shields 18 or insulators 32 or 51 has a an effect upon how deeply the ionic solution is transported into the skin. For a range of thickness between very thick and very thin shields 18 or insulators 32 or 51, the electric field lines 12 are still relatively short, and hence require relatively low energy to transport the ionic ;.
solution. The electric field lines 12 are sufficiently long, however, so that the ionic solution is still transported by the electric field lines 12 to the epidermis at C and dermis at D for transfer to the vasculature at E. To some extent, the preferred range extends from 0.01 to 1.0 inches or .025 to 2.s centimeters. The most beneficial range is 0.10 to 0.62 centimeters.
The stratum corneum at F is essentially unhydrated protein. Since there are few ions in that material the impedence is high. The granulated epidermis C is the sight of transformation from the well hydrated basal epidermis C to the unhydrated stratum corneum F. Here the impedence falls off as the tissue increases in hydration, also because of salt content. From the basal epidermis C inward, tissues are well hydrated, and salt solutions isotonic whereby the impedence nears its minimum. Of course, the impedence will vary from person to person and place to place on any given person, however, it is known that the impedence is high at the stratum corneum F gradually decreasing to the granulated epidermis where it drops significantly and remains low into and through the basal epidermis C and the dermis D. For very thin shields 18 or insulators 32 or 51 in a repeated array 10 or 10' or in an electrode 45 such as disclosed and described as the embodiments in this specification, the electric field lines 12 pass through the stratum corneum F and maybe the upper layers of the granulated epidermis C.
, , 20228~
These paths are preferred in spite of the high resisitivity or impedence of the stratum corneum F
because the path lengths of the electric field lines 12 are short. Since ionic solution flows during transportation along the electric field lines 12, it can be appreciated that the ionic solution is transported well into the stratum corneum F then flows backup to the receiver. Thus, for very thin insulators, little of the medication reaches the blood stream. Moreover, this approach has the greatest likelihood to actually short out due to the close spacing of either the transmitters and receivers 11 and 15, the active and indifferent members 28 and 30 or the first and second conductors 46 and 49.
If the shields 18 or insulators 32 or 51 are very thick, the electric field lines 12 lengthen as they take the path of least impedence through the stratum corneum F and the hydrated tissue C below the stratum corneum F so they may return through the stratum corneum F to the next adjacent transmitter 11 or receiver 15, member 28 or 30, or conductor 46 or 49, requiring greater levels of energy. This path is most effective for transportation of ionic solution to the dermis D, however, it requires the greatest amount of energy which increases the amount of skin damage or irritation. An optimum thickness of insulator 32 or 51 or shield 18 exists wherein the field lines are deep enough to cause ions to reach the bloodstream, and the length of each field line is short enough to minimize skin irritation.
2~22824 Figure 4 is a plot on a graph of the petechial skin damage of an experiment with iontophoretically transported lidocaine. Along the vertical axis of that graph is shown the damage assessment score which is the number of petechial (small, punctate, red spots in the skin) observed under the electrode.
This axis is linearly divided, the horizontal axis shows current density necessary in order to transport ionic solution. The current density is in microamps per sguare centimeter and the scale is a log scale.
The significant data are represented by two areas of the plot. The first area of the graph is plotted above the current density range of 25. to 75 microamperes per square centimeter for a typical iontophoretic electrode of the type in Figure S
wherein the active and indifferent members are spaced apart and are of no particular shape as can be seen, damage to the skin begins to occur at current densities of about 25 The second plot of data in the range of 500 to 1000 microamperes per square centimeter represent the experiments with the claimed invention. The difference in these data are apparent in that the amount of current density that can be used without damage to the skin is at least ten times greater than with the typical electrode in Figure 5. Another way of looking at the data is that current between 100 and 500 microamperes per square centimeter can be used to transport drug without measurable damage using this invention. Note that several data points are not typical of that which is expected; those data points show the difficulty of transportation caused by variations of impedence of the skin. These particular data were obtained during experiments with pigs where the damage was assessed after each test upon a different area of the animal's skin.
The specific material described and the particular configurations of the preferred and alternate embodiments may be changed without departing from the scope of the invention covered by the claims which follow.
Claims (17)
1. An iontophoretic electrode array for placement against the skin in transdermal transport of ionic solutions through mammalian skin comprising:
a plurality of ion transmitters for establishing electric field lines in an area of the skin and for transmission of ions along the field lines, each transmitter having a pair of longer sides and a pair of shorter sides;
a plurality of receivers in position for accepting ions flowing along the electric field lines in the area of the skin, each receiver having a pair of longer sides and a pair of shorter sides; and a plurality of shields of a substance to resist the flow of ions thereacross, the shields interposed and located between adjacent transmitters and receivers along the longer sides thereof so that the transmitters, shields and receivers are arranged in at least a sequence of transmitter, shield, receiver, shield so that the electric field lines are generally transverse to the longer sides as they pass through the area of the skin.
a plurality of ion transmitters for establishing electric field lines in an area of the skin and for transmission of ions along the field lines, each transmitter having a pair of longer sides and a pair of shorter sides;
a plurality of receivers in position for accepting ions flowing along the electric field lines in the area of the skin, each receiver having a pair of longer sides and a pair of shorter sides; and a plurality of shields of a substance to resist the flow of ions thereacross, the shields interposed and located between adjacent transmitters and receivers along the longer sides thereof so that the transmitters, shields and receivers are arranged in at least a sequence of transmitter, shield, receiver, shield so that the electric field lines are generally transverse to the longer sides as they pass through the area of the skin.
2. The electrode array of claim 1 wherein an aspect ratio of the longer to the shorter sides of the respective transmitters and receivers is greater than one and one half.
3. The electrode array of claim 2 wherein the aspect ratio is in the range of four to twenty.
4. The electrode array of claim 1 wherein the transmitters include a material having an ionic medication.
5. The electrode array of claim 4 wherein the material is a porous substance with space therein for the ionic medication.
6. The electrode array of claim 4 wherein the material is a hydrogel so formulated to include the ionic medication.
7. The electrode array of claim 1 wherein the receivers have a material having an electrolyte.
8. The electrode array of claim 7 wherein the material is a porous substance with space therein for the electrolyte.
9. The electrode array of claim 1 wherein each transmitter has a matrix structure with space therein for an ionic medication and each receiver has a matrix structure with space therein for an electrolyte.
10. The electrode array of claim 9 wherein the matrix structure is a porous substance.
11. The electrode array of claim 1 including a support holding a plurality of the sequences of the transmitters and the receivers separated by the interposed shields.
12. The electrode array of claim 11 having a source of electrical power wherein the support has current carrying contacts positioned thereon and connecting the transmitters and the receivers in circuit with the source of electrical power.
13. The electrode array of claim 12 wherein the source of electrical power is carried in the support.
14. The electrode array of claim 1 wherein the transmitters and the receivers are rectangular plate like in shape with a pair of opposed parallel major surfaces bound by sides set perpendicular thereto.
15. The electrode array of claim 14 wherein the support has a first set of current carrying contacts connected in circuit with the source of electrical power and positioned thereon and exposed to connect with one of the sides of each of the transmitters and wherein the support has a second set of current carrying contacts positioned thereon and exposed to connect one of the sides of each of the receivers in circuit with the source of electrical power.
16. The electrode array of claim 15 wherein the first and second sets of the contacts are mounted on the support in spaced apart relation relative to each other and are located on a face thereof, the first set of contacts connected to the transmitters are arranged in circuit for passing current from the source of electrical power to the transmitters and the second set of contacts connected to the receivers are arranged in circuit for receiving ions from the receivers so that there is current flow from the source of electrical power to the transmitters and there is current flow from the receivers to the source of electrical power when ions flow between the sides of the transmitters opposite the first set of contacts and the adjacent sides of the receivers opposite the second set of contacts.
17. The electrode array of claim 16 wherein the support includes recesses and each of the shields extends beyond the face thereon for the first and second contact sets into one recess in the support so that each recess locates the transmitters and the first set of contacts in circuit and aligns the receivers and the second set of contacts in circuit.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US412,056 | 1989-09-25 | ||
| US07/412,056 US4950229A (en) | 1989-09-25 | 1989-09-25 | Apparatus for an electrode used for iontophoresis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2022824A1 CA2022824A1 (en) | 1991-03-26 |
| CA2022824C true CA2022824C (en) | 1995-05-02 |
Family
ID=23631411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002022824A Expired - Fee Related CA2022824C (en) | 1989-09-25 | 1990-08-07 | Apparatus for an electrode and method used for iontophoresis |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US4950229A (en) |
| EP (1) | EP0419820B1 (en) |
| JP (1) | JPH03133464A (en) |
| AT (1) | ATE129416T1 (en) |
| CA (1) | CA2022824C (en) |
| DE (1) | DE69023199T2 (en) |
| DK (1) | DK0419820T3 (en) |
| ES (1) | ES2081326T3 (en) |
| IE (1) | IE902854A1 (en) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6956032B1 (en) * | 1986-04-18 | 2005-10-18 | Carnegie Mellon University | Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods |
| US4950229A (en) * | 1989-09-25 | 1990-08-21 | Becton, Dickinson And Company | Apparatus for an electrode used for iontophoresis |
| US5334138A (en) * | 1990-03-15 | 1994-08-02 | North Carolina State University | Method and composition for increased skin concentration of active agents by iontophoresis |
| DE4014913C2 (en) * | 1990-05-10 | 1996-05-15 | Lohmann Therapie Syst Lts | Miniaturized transdermal therapeutic system for iontophoresis |
| US5160316A (en) * | 1990-09-10 | 1992-11-03 | Henley Julian L | Iontophoretic drug delivery apparatus |
| US5169384A (en) * | 1991-08-16 | 1992-12-08 | Bosniak Stephen L | Apparatus for facilitating post-traumatic, post-surgical, and/or post-inflammatory healing of tissue |
| US5310403A (en) * | 1992-05-18 | 1994-05-10 | Becton, Dickinson And Company | Iontophoretic drug delivery device and circuit therefor |
| US5331979A (en) * | 1992-07-27 | 1994-07-26 | Henley Julian L | Iontophoretic cigarette substitute |
| US5427585A (en) * | 1993-03-29 | 1995-06-27 | Bettinger; David S. | On-demand iontophoretic system |
| US5667487A (en) * | 1993-04-07 | 1997-09-16 | Henley; Julian L. | Ionosonic drug delivery apparatus |
| US5458569A (en) * | 1993-06-08 | 1995-10-17 | Becton Dickinson And Company | Wearable iontophoresis system |
| US5415629A (en) * | 1993-09-15 | 1995-05-16 | Henley; Julian L. | Programmable apparatus for the transdermal delivery of drugs and method |
| AU7923794A (en) * | 1993-09-30 | 1995-04-18 | Becton Dickinson & Company | Iontophoretic drug delivery system and method |
| US5540669A (en) * | 1993-09-30 | 1996-07-30 | Becton, Dickinson And Company | Iontophoretic drug delivery system and method for using same |
| US5556528A (en) * | 1994-05-10 | 1996-09-17 | Biotechnology Research & Development Corporation | Structures with field responsive permeation control |
| US5540654A (en) * | 1994-09-02 | 1996-07-30 | North Carolina State University | Iontophoretic electrode |
| US5990179A (en) * | 1995-04-28 | 1999-11-23 | Alza Corporation | Composition and method of enhancing electrotransport agent delivery |
| AU6260896A (en) * | 1995-06-06 | 1996-12-24 | Board Of Regents, The University Of Texas System | Electrode system in iontophoretic treatment devices |
| US5897522A (en) * | 1995-12-20 | 1999-04-27 | Power Paper Ltd. | Flexible thin layer open electrochemical cell and applications of same |
| US6385487B1 (en) | 1996-05-08 | 2002-05-07 | Biophoretic Therapeutic Systems, Llc | Methods for electrokinetic delivery of medicaments |
| US5676648A (en) | 1996-05-08 | 1997-10-14 | The Aps Organization, Llp | Iontophoretic drug delivery apparatus and method for use |
| WO1997048444A1 (en) * | 1996-06-19 | 1997-12-24 | Becton Dickinson And Company | Iontophoretic delivery of cell adhesion inhibitors |
| WO1998035722A1 (en) | 1997-02-17 | 1998-08-20 | Kowa Co., Ltd. | Device for iontophoresis |
| US5991655A (en) * | 1997-03-03 | 1999-11-23 | Drug Delivery Systems, Inc. | Iontophoretic drug delivery device and method of manufacturing the same |
| US6119036A (en) | 1997-03-26 | 2000-09-12 | The Board Of Regents Of The University Of Oklahoma | Iontophoretic transdermal delivery device |
| EP1030560B1 (en) | 1997-10-09 | 2007-09-26 | Emory University | Method and devices for transdermal delivery of lithium |
| USRE37796E1 (en) | 1997-12-16 | 2002-07-23 | Biophoretic Therapeutic Systems, Llc | Methods for iontophoretic delivery of antiviral agents |
| EP0970719A3 (en) | 1998-07-08 | 2000-08-23 | Nitto Denko Corporation | Electrode structure |
| US6678556B1 (en) * | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
| EP2428250A1 (en) * | 1998-07-13 | 2012-03-14 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US7922709B2 (en) | 1998-07-13 | 2011-04-12 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
| US6192270B1 (en) | 1998-08-14 | 2001-02-20 | Genetronics, Inc. | Apparatus and method for the delivery of drugs and genes into tissue |
| WO2000012172A1 (en) * | 1998-08-31 | 2000-03-09 | Birch Point Medical Inc. | Controlled dosage drug delivery system |
| US6148231A (en) * | 1998-09-15 | 2000-11-14 | Biophoretic Therapeutic Systems, Llc | Iontophoretic drug delivery electrodes and method |
| JP2002536133A (en) * | 1999-02-10 | 2002-10-29 | ジーエムピー ドラッグ デリバリー インコーポレイテッド | Iontophoretic, electroporation and combination patches for local drug delivery |
| US6294063B1 (en) | 1999-02-12 | 2001-09-25 | Board Of Regents, The University Of Texas System | Method and apparatus for programmable fluidic processing |
| US6477410B1 (en) * | 2000-05-31 | 2002-11-05 | Biophoretic Therapeutic Systems, Llc | Electrokinetic delivery of medicaments |
| US7127285B2 (en) | 1999-03-12 | 2006-10-24 | Transport Pharmaceuticals Inc. | Systems and methods for electrokinetic delivery of a substance |
| US6792306B2 (en) | 2000-03-10 | 2004-09-14 | Biophoretic Therapeutic Systems, Llc | Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor |
| WO2001038958A1 (en) * | 1999-11-24 | 2001-05-31 | Center For Advanced Science And Technology Incubation, Ltd. | Method and device for stimulating tactile sensation by electricity |
| US6687536B1 (en) * | 1999-12-09 | 2004-02-03 | Iomed, Inc. | Connection system for an iontophoretic drug delivery device |
| US6421561B1 (en) * | 1999-12-30 | 2002-07-16 | Birch Point Medical, Inc. | Rate adjustable drug delivery system |
| US20040092860A1 (en) * | 2000-07-26 | 2004-05-13 | Dev Nagendu B. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US9084879B2 (en) * | 2002-01-22 | 2015-07-21 | Encore Medical Asset Corporation | Method and device for the iontophoretic delivery of a drug |
| US7220778B2 (en) * | 2003-04-15 | 2007-05-22 | The General Hospital Corporation | Methods and devices for epithelial protection during photodynamic therapy |
| KR20070011240A (en) * | 2003-11-13 | 2007-01-24 | 알자 코포레이션 | System and method for transdermal delivery |
| US20050234516A1 (en) * | 2004-02-16 | 2005-10-20 | Gueret Jean-Louis H | Treatment kit, composite structure, electric exciter, and cosmetic treatment method |
| WO2005084275A2 (en) | 2004-02-27 | 2005-09-15 | Iomed, Inc. | Iontophoretic electrode |
| WO2006085905A1 (en) * | 2004-05-28 | 2006-08-17 | Board Of Regents, The University Of Texas System | Programmable fluidic processors |
| BRPI0616165A2 (en) * | 2005-09-15 | 2011-06-07 | Tti Ellebeau Inc | rod type iontophoresis device |
| AU2006299520A1 (en) * | 2005-09-30 | 2007-04-12 | Tti Ellebeau, Inc. | Iontophoresis device to deliver multiple active agents to biological interfaces |
| JP2009509634A (en) * | 2005-09-30 | 2009-03-12 | Ｔｔｉ・エルビュー株式会社 | Functionalized microneedle transdermal drug delivery system, apparatus and method |
| US20070078445A1 (en) * | 2005-09-30 | 2007-04-05 | Curt Malloy | Synchronization apparatus and method for iontophoresis device to deliver active agents to biological interfaces |
| WO2007079189A2 (en) * | 2005-12-30 | 2007-07-12 | Tti Ellebeau, Inc. | System and method for remote based control of an iontophoresis device |
| WO2008030497A2 (en) * | 2006-09-05 | 2008-03-13 | Tti Ellebeau, Inc. | Transdermal drug delivery systems, devices, and methods using inductive power supplies |
| EP2101863A2 (en) * | 2006-11-24 | 2009-09-23 | Koninklijke Philips Electronics N.V. | Iontophoretic device |
| CA2671069A1 (en) * | 2006-12-01 | 2008-06-12 | Tti Ellebeau, Inc. | Systems, devices, and methods for powering and/or controlling devices, for instance transdermal delivery devices |
| US20080188791A1 (en) * | 2007-02-02 | 2008-08-07 | Difiore Attilio E | Active iontophoresis delivery system |
| US8197844B2 (en) | 2007-06-08 | 2012-06-12 | Activatek, Inc. | Active electrode for transdermal medicament administration |
| JP2010529897A (en) * | 2007-06-15 | 2010-09-02 | ニトリツク・バイオ・セラピユーテイクス・インコーポレーテツド | Current concentration mitigation method and system for electrokinetic drug delivery |
| EP2164418B1 (en) * | 2007-06-27 | 2014-01-08 | The General Hospital Corporation | Apparatus for optical inhibition of photodynamic therapy |
| US8862223B2 (en) | 2008-01-18 | 2014-10-14 | Activatek, Inc. | Active transdermal medicament patch and circuit board for same |
| FR3000897B1 (en) * | 2013-01-14 | 2016-10-28 | Feeligreen | AUTORGANIZED ELECTROSTIMULATION AND / OR IONTOPHORESIS DEVICE |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2047308A (en) * | 1934-05-05 | 1936-07-14 | T M Chapman S Sons Co | Electrical therapeutic pad |
| US3848608A (en) * | 1973-07-23 | 1974-11-19 | Gen Electric | Subject integument spatial stimulator |
| US4325367A (en) * | 1977-06-13 | 1982-04-20 | Robert Tapper | Iontophoretic treatment apparatus |
| US4543958A (en) * | 1979-04-30 | 1985-10-01 | Ndm Corporation | Medical electrode assembly |
| JPS56501274A (en) * | 1979-10-10 | 1981-09-10 | ||
| DE3020789A1 (en) * | 1980-05-31 | 1982-01-07 | Rudolf Dr.-Ing. Lugano-Cassarate Steineck | DC therapy instrument - has rechargeable button cells applied directly to skin of patient |
| US4416274A (en) * | 1981-02-23 | 1983-11-22 | Motion Control, Inc. | Ion mobility limiting iontophoretic bioelectrode |
| DE3273269D1 (en) * | 1981-03-06 | 1986-10-23 | Medtronic Inc | Iontophoretic electrode |
| US4820263A (en) * | 1981-03-06 | 1989-04-11 | Medtronic, Inc. | Apparatus and method for iontophoretic drug delivery |
| US4731926A (en) * | 1985-02-19 | 1988-03-22 | Drug Delivery Systems Inc. | Method of manufacturing disposable and/or replenishable transdermal drug applicators |
| US4622031A (en) * | 1983-08-18 | 1986-11-11 | Drug Delivery Systems Inc. | Indicator for electrophoretic transcutaneous drug delivery device |
| US4883457A (en) * | 1983-08-18 | 1989-11-28 | Drug Delivery Systems Inc. | Disposable and/or replenishable transdermal drug applicators and methods of manufacturing same |
| DE3505900A1 (en) * | 1985-02-21 | 1986-08-21 | Bayer Ag, 5090 Leverkusen | 2,4-DICHLORTHIAZOLE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
| DE3703321A1 (en) * | 1986-09-01 | 1988-03-10 | Transcutan Gmbh | Therapeutic device for application of electrical current |
| US4865582A (en) * | 1987-06-05 | 1989-09-12 | Drug Delivery Systems Inc. | Disposable transdermal drug applicators |
| EP0398960B1 (en) * | 1988-01-21 | 1995-12-06 | Massachusetts Institute Of Technology | Transport of molecules across tissue using electroporation |
| IL86076A (en) * | 1988-04-14 | 1992-12-01 | Inventor S Funding Corp Ltd | Transdermal drug delivery device |
| US5088977A (en) * | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US4950229A (en) * | 1989-09-25 | 1990-08-21 | Becton, Dickinson And Company | Apparatus for an electrode used for iontophoresis |
| US5047007A (en) * | 1989-12-22 | 1991-09-10 | Medtronic, Inc. | Method and apparatus for pulsed iontophoretic drug delivery |
-
1989
- 1989-09-25 US US07/412,056 patent/US4950229A/en not_active Expired - Lifetime
-
1990
- 1990-06-28 US US07/545,214 patent/US5284471A/en not_active Expired - Lifetime
- 1990-08-07 CA CA002022824A patent/CA2022824C/en not_active Expired - Fee Related
- 1990-08-07 IE IE285490A patent/IE902854A1/en unknown
- 1990-08-09 EP EP90115288A patent/EP0419820B1/en not_active Expired - Lifetime
- 1990-08-09 DE DE69023199T patent/DE69023199T2/en not_active Expired - Fee Related
- 1990-08-09 ES ES90115288T patent/ES2081326T3/en not_active Expired - Lifetime
- 1990-08-09 DK DK90115288.4T patent/DK0419820T3/en active
- 1990-08-09 AT AT90115288T patent/ATE129416T1/en not_active IP Right Cessation
- 1990-09-25 JP JP2255030A patent/JPH03133464A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| CA2022824A1 (en) | 1991-03-26 |
| DE69023199T2 (en) | 1996-05-02 |
| EP0419820A3 (en) | 1991-09-11 |
| ATE129416T1 (en) | 1995-11-15 |
| US5284471A (en) | 1994-02-08 |
| ES2081326T3 (en) | 1996-03-01 |
| DK0419820T3 (en) | 1995-12-04 |
| DE69023199D1 (en) | 1995-11-30 |
| JPH0474030B2 (en) | 1992-11-25 |
| EP0419820A2 (en) | 1991-04-03 |
| JPH03133464A (en) | 1991-06-06 |
| IE902854A1 (en) | 1991-04-10 |
| EP0419820B1 (en) | 1995-10-25 |
| US4950229A (en) | 1990-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2022824C (en) | Apparatus for an electrode and method used for iontophoresis | |
| AU644793B2 (en) | Method and apparatus for iontophoretic drug delivery | |
| KR940000071B1 (en) | Transdermal drug applicator | |
| US5931804A (en) | Transdermal drug applicator and electrodes therefor | |
| US5087240A (en) | Transdermal drug patch with conductive fibers | |
| US4640689A (en) | Transdermal drug applicator and electrodes therefor | |
| US4921475A (en) | Transdermal drug patch with microtubes | |
| US4919648A (en) | High tack drug patch | |
| US5651768A (en) | Transdermal drug applicator and electrodes therefor | |
| EP0147524B1 (en) | Applicator for the non-invasive transcutaneous delivery of medicament | |
| EP0240593B1 (en) | Improved transdermal drug applicator and electrodes therefor | |
| US7395110B2 (en) | Electrode apparatus and method for the delivery of drugs and genes into tissue | |
| US5356632A (en) | Transdermal drug delivery device | |
| US6129696A (en) | Transdermal drug applicator | |
| US5053001A (en) | Transdermal drug delivery device with multiple reservoirs | |
| JP2001190693A (en) | Electrode structural body | |
| JP2821267B2 (en) | Apparatus and method for supplying a drug by iontophoresis | |
| JP2000176024A (en) | Electrode structural body |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |